Sanofi Profit Margin 2006-2018 | SNY

Current and historical gross margin, operating margin and net profit margin for Sanofi (SNY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Sanofi net profit margin as of March 31, 2018 is 12.2%.
Sanofi Annual Profit Margins
Sanofi Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $110.782B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.718B 18.27
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
Novartis AG (NVS) Switzerland $200.739B 17.21
AbbVie (ABBV) United States $131.784B 11.70
Eli Lilly (LLY) United States $120.858B 21.25
Novo Nordisk (NVO) Denmark $112.280B 18.23
AstraZeneca (AZN) United Kingdom $97.289B 12.08
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13